Nanobiotix
Company

Last deal

$4.98M
Local Amount - EUR 4.6M

Amount

Post-IPO Equity

Stage

04.12.2023

Date

3

all rounds

$358.46M

Total amount

date founded

Financing round

General

About Company
Nanobiotix is a nanomedicine company developing cancer therapeutics.

Industry

Sector :

Subsector :

founded date

01.01.2003

founders

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The Paris-based company, founded in 2003, develops NanoXray products that use proprietary nanotechnology to increase the efficacy of radiotherapy for cancer patients. Its lead product candidate, NBTXR3, is a preclinical research program for cancer immunotherapies. Nanobiotix's Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. The company is listed on Euronext and Nasdaq and has affiliates in the US, Spain, and Germany.
Contacts

Phone number

Social url

Similar Companies
999
Arrogene

Arrogene

Arrogene develops nano-biopolymers and technologies for cancer therapeutics and diagnostics.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Santa Monica, CA, USA

total rounds

7

total raised

$7.9M
Duo Oncology

Duo Oncology

Duo Oncology develops nanoparticle technology to cure established tumors.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Pittsburgh, PA, USA

total rounds

1

total raised

$2.7M
ZTI Biosciences

ZTI Biosciences

ZTI Biosciences is a South Korean company that develops nanomedicine therapeutics for cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Suwon-si, Gyeonggi-do, South Korea

total rounds

2

total raised

$1.65M
Cellics Therapeutics

Cellics Therapeutics

Cellics develops innovative biomimetic nanomedicines to treat and prevent diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Diego, CA, USA

total rounds

5

total raised

$36.94M

Financials

Funding Rounds
11
3

Number of Funding Rounds

$358.46M

Money Raised

Their latest funding was raised on 04.12.2023. Their latest investor Johnson & Johnson Innovation – JJDC. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
04.12.2023
1
$4.98M
Local Amount - EUR 4.6M
01.11.2023
1
$29.97M
Local Amount - EUR 28.4M
12.05.2021
$220M
Johnson & Johnson Innovation – JJDC

Johnson & Johnson Innovation – JJDC

JJDC helps innovative healthcare ideas become real solutions for patients.

Sector

Health Care Providers

Subsector

Health Care Services

Keywords

Health Care

Location

Cambridge, MA, USA

count Of Investments

76

count Of Exists

3
Co-Investors
Investors
9
3

Number of lead investors

9

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series C
No
Series C
Johnson & Johnson Innovation – JJDC

Johnson & Johnson Innovation – JJDC

JJDC helps innovative healthcare ideas become real solutions for patients.

Sector

Health Care Providers

Subsector

Health Care Services

Keywords

Health Care

Location

Cambridge, MA, USA

count Of Investments

76

count Of Exists

3
Apicap

Apicap

APICAP offers innovative investment opportunities for institutional and private investors.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Finance, Venture Capital

Location

Paris, France

count Of Investments

41

count Of Exists

12
Seventure Partners

Seventure Partners

Seventure Partners is a French venture capital firm specializing in technology and life sciences companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services, Finance

Location

Paris, France

count Of Investments

239

count Of Exists

46

People

Founders
1
Laurent Levy
Laurent Levy

Laurent Levy

Laurent LEVY, Ph.D., co-founder and President of the Executive Board: Laurent holds a doctorate in physical chemistry, specialized in nanomaterials, from the Pierre and Marie Curie University (Paris) and from the CEA (Commissariat à l’Énergie Atomique et aux Énergies Alternatives) and a DEA (advanced studies and diplomas) in physics of condensed matter from the UPVI-ESPCI (Paris). He has extensive experience in sciences and techniques related to nanotechnologies, a field in which he worked for more than 10 years. His research at the frontier of biotechnology and nanotechnologies has resulted in the development of a number of concrete applications such as NanoXray, which could open a new method for cancer treatment. For many years, Laurent was a consultant in the development of application of nanotechnologies with large companies such as Sanofi (pharma), Guerbet (medical imaging), Rhodia (chemistry), as well as for biotechnology start-ups. Laurent is the author of 35 international scientific publications and communications, has applied for several patents and completed his training by a post-doctoral fellowship at the Institute for Lasers, Photonics and Biophotonics, SUNY (State University of New York), Buffalo, USA.

current job

Valbiotis
Valbiotis

organization founded

1

Laurent Levy

Employee Profiles
6

Bart Van Rhijn

Chief Financial Officer

Mikaela Dimitriu

Mikaela Dimitriu

Vice President Global Head Medical Affairs

Philippe Mauberna

Philippe Mauberna

CFO

Elsa Borghi

Elsa Borghi

Chief Medical Officer

Laurent Levy

Laurent Levy

Co-Founder, Persident & CEO

Kader Boussaha

CFO & COO

Activity

Recent News
17
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week